Tea Gunde

Tea joined Numab in 2011, establishing Numab’s antibody discovery platform. From 2004 to 2011 Tea was Head of PK & PD at ESBATech where she was responsible for the pharmacodynamic and pharmacokinetic characterization of antibody fragments. She led preclinical discovery and development projects in the field of ophthalmology and immuno-oncology. Tea was instrumental in the discovery and the preclinical development of brolucizumab/Beovu® a best-in-class anti-VEGF fragment for the treatment of age-related macular edema. She graduated with a degree in Molecular Biology and Immunology from the University of Zurich and obtained her PhD in Molecular Biology from the University of Zurich.